SGTX News and Press, Sigilon Therapeutics Inc. From 12/20/21

Gainers: uCloudlink Group  (NASDAQ:UCL) +15%. Quantum-Si Incorporated QSI +10%. Micron Technology  MU +7%. Braze BRZE +6%. JAKKS Pacific (NASDAQ:JAKK) +6%. Losers: CytomX Therapeutics CTMX -29%. DBV Technologies  (NASDAQ:DBVT) -13%. Sigilon Therape...

Sigilon Therapeutics (NASDAQ:SGTX) announces a strategic reprioritization to focus on MPS-1 and diabetes. In November, the company reported that fibrosed spheres were observed during a retrieval procedure for the third patient enrolled in its Phase 1/2 study of SIG-001 in hemophilia A. SGTX p...

- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – - Workforce reduction of approximately 38% – - Anticipated cash runway extended into 2024 – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWI...

Gainers: Stitch Fix  (NASDAQ:SFIX) +2%. Fate Therapeutics (NASDAQ:FATE) +2%. Frequency Therapeutics (NASDAQ:FREQ) +1%. Criteo  (NASDAQ:CRTO) +1%. EVgo  (NASDAQ:EVGO) +1%. Losers: Nexters  (NASDAQ:GDEV) -3%. Ocular Therapeutix (NASDAQ:OCUL) -2%. Sig...

Sigilon Therapeutics (SGTX -3.3%) is trading lower after Jefferies downgraded the stock to Hold from Buy in reaction to the company’s announcement on Monday about a case of fibrosis found in its Phase 1/2 study for SIG-001 in hemophilia A. Noting that the event was “unexpec...

Having observed fibrosed spheres in a patient who underwent its Phase 1/2 study of SIG-001 in hemophilia A, Sigilon Therapeutics (NASDAQ:SGTX) says that the findings could have an impact on the timing of the start of dosing in a future Phase 1/2 trial of SIG-005 in mucopolysaccharidosis type ...

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that fibrosed spheres were observed dur...

Sigilon Therapeutics (NASDAQ:SGTX): Q3 GAAP EPS of -$0.63 beats by $0.03. Revenue of $1.95M (-53.6% Y/Y) misses by $0.95M. Press Release For further details see: Sigilon Therapeutics EPS beats by $0.03, misses on revenue

Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021 Company appoints May Orfali, M.D., M.B.A, as...

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive...